应用染色体微阵列分析和外显子组测序对先天性心脏缺陷胎儿遗传变异的综合评估
本研究对2018年2月至2019年12月转诊至本科室进行遗传学检测的360例经超声心动图检出先天性心脏缺陷的非选择性单胎胎儿,先常规行染色体微阵列分析(CMA)检测非整倍体和拷贝数变异(CNV),对CMA未发现非整倍体或致病性CNV者再行外显子组测序(ES)。总体阳性遗传学诊断率为23.3%(84/360),其中CMA检出染色体异常60例(16.7%),ES额外检出序列变异24例(6.7%)。非孤立性先天性心脏缺陷胎儿的致病性和可能致病性遗传变异检出率(38.6%,32/83)显著高于孤立性者(18.8%,52/277)(P < 0.001),差异主要源于两组非整倍体频率不同。作者结论认为,对CMA未发现染色体异常或致病性CNV的先天性心脏缺陷胎儿,无论是否孤立,均应提供ES检测。
要点
- CMA在先天性心脏缺陷胎儿中检出染色体异常16.7%(60/360),ES在CMA阴性者中额外检出序列变异6.7%(24/360)。
- 非孤立性先天性心脏缺陷胎儿致病/可能致病变异检出率38.6%(32/83),高于孤立性者18.8%(52/277),P < 0.001。
- 遗传缺陷患病率最高的亚组为房室间隔缺损(36.8%)、室间隔缺损伴或不伴房间隔缺损(28.4%)、圆锥动脉干缺陷(22.2%)和右心室流出道梗阻(20.0%)。
核心结论
- 先天性心脏缺陷胎儿中染色体异常检出率为16.7%(60/360),CMA阴性者中ES额外检出序列变异6.7%(24/360)。
- 非孤立性先天性心脏缺陷胎儿的致病性和可能致病性遗传变异检出率(38.6%,32/83)显著高于孤立性者(18.8%,52/277),P < 0.001,差异主要源于两组非整倍体频率不同。
- 作者结论认为,对CMA未发现染色体异常或致病性CNV的先天性心脏缺陷胎儿,无论是否孤立,均应提供ES检测。
研究设计与样本
- 本研究为对360例非选择性单胎先天性心脏缺陷胎儿的研究,胎儿均经超声心动图检出,于2018年2月至2019年12月转诊至本科室进行遗传学检测。
- 先常规行CMA检测非整倍体和拷贝数变异(CNV),对CMA未发现非整倍体或致病性CNV的病例再行ES。
诊断标准与关键数值
- 总体阳性遗传学诊断84例(23.3%),其中CMA检出染色体异常60例(16.7%),ES额外检出序列变异24例(6.7%)。
- 非孤立性先天性心脏缺陷组致病性和可能致病性遗传变异检出率38.6%(32/83),孤立性组18.8%(52/277),P < 0.001。
- 各亚组遗传缺陷患病率:房室间隔缺损36.8%,室间隔缺损伴或不伴房间隔缺损28.4%,圆锥动脉干缺陷22.2%,右心室流出道梗阻20.0%。
- 鉴定出两个新发错义突变(c.2447G>C,p.Arg816Pro;c.1171C>T,p.Arg391Cys)及PLD1变异导致的新表型。
临床应用与阅片要点
- 作者结论认为,对CMA未发现染色体异常或致病性CNV的先天性心脏缺陷胎儿,无论是否孤立,均应提供ES检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate comprehensively, using chromosomal microarray analysis (CMA) and exome sequencing (ES), the prevalence of chromosomal abnormalities and sequence variants in unselected fetuses with congenital heart defect (CHD) and to evaluate the potential diagnostic yields of CMA and ES for different CHD subgroups.
METHODS: This was a study of 360 unselected singleton fetuses with CHD detected by echocardiography, referred to our department for genetic testing between February 2018 and December 2019. We performed CMA, as a routine test for aneuploidy and copy number variations (CNV), and then, in cases without aneuploidy or pathogenic CNV on CMA, we performed ES.
RESULTS: Overall, positive genetic diagnoses were made in 84 (23.3%) fetuses: chromosomal abnormalities were detected by CMA in 60 (16.7%) and sequence variants were detected by ES in a further 24 (6.7%) cases. The detection rate of pathogenic and likely pathogenic genetic variants in fetuses with non-isolated CHD (32/83, 38.6%) was significantly higher than that in fetuses with isolated CHD (52/277, 18.8%) (P < 0.001), this difference being due mainly to the difference in frequency of aneuploidy between the two groups. The prevalence of a genetic defect was highest in fetuses with an atrioventricular septal defect (36.8%), ventricular septal defect with or without atrial septal defect (28.4%), conotruncal defect (22.2%) or right ventricular outflow tract obstruction (20.0%). We also identified two novel missense mutations (c.2447G>C, p.Arg816Pro; c.1171C>T, p.Arg391Cys) and a new phenotype caused by variants in PLD1.
CONCLUSIONS: Chromosomal abnormalities were identified in 16.7% and sequence variants in a further 6.7% of fetuses with CHD. ES should be offered to all pregnant women with a CHD fetus without chromosomal abnormality or pathogenic CNV identified by CMA, regardless of whether the CHD is isolated. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Qiao F, Wang Y, Zhang C, et al. Comprehensive evaluation of genetic variants using chromosomal microarray analysis and exome sequencing in fetuses with congenital heart defect. Ultrasound Obstet Gynecol. 2021. PMID: 33142350. doi:10.1002/uog.23532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。